tiprankstipranks
Analyst Profile
Followed by 32 other investors
.
Kalpit Patel

Kalpit Patel

B.Riley Financial
Wall Street Analyst
Ranked #7,937 out of 8,054 Analysts on TipRanks (#21,136 out of 21,594 overall experts)

Success Rate

25%
13 out of 52 Profitable Transactions

Average Return

-29.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Kalpit Patel's ratings since 2021 and opened each position for the duration of 1 Year:
25.00% of your transactions would have been profitable with an average return of -29.0%

Stock Rating Distribution

72Ratings
88.89% Buy
11.11% Hold
0.00% Sell
Distribution of Kalpit Patel's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Mink Therapeutics, Inc.
(INKT)
Rating Type:Buy
Dates:May 11, 2022 - Jan 01, 1970
Gain:151.90%
The most profitable rating made by Kalpit Patel

Kalpit Patel's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Forte Biosciences
Nov 26, 2021
Hold
Assigned
0%
-11.63%
6
Magenta Therapeutics
Jan 24, 2022
Buy
Reiterated
$6.00
(270.37% Upside)
0%
-75.93%
8
IN8bio
Jan 24, 2022
Buy
Reiterated
$9.00
(350.00% Upside)
0%
-65.90%
4
Allogene Therapeutics
Feb 27, 2022
Buy
Reiterated
$21.00
(31.41% Upside)
50%
+2.07%
8
Bicycle Therapeutics
Apr 13, 2022
Hold
Downgraded
$33.00
(29.67% Upside)
0%
-49.78%
6
Kymera Therapeutics
May 04, 2022
Buy
Reiterated
$50.00
(69.20% Upside)
100%
+36.50%
2
MiNK Therapeutics
May 11, 2022
Buy
Reiterated
$7.00
(102.90% Upside)
67%
+24.17%
4
Journey Medical Corp
May 11, 2022
Buy
Reiterated
$10.00
(188.18% Upside)
20%
-25.82%
6
Vincerx Pharma Inc
Jun 07, 2022
Buy
Reiterated
$6.00
(275.00% Upside)
0%
-64.80%
5
Entera Bio
Jul 19, 2022
Buy
Reiterated
$5.00
(174.74% Upside)
17%
-46.03%
9
List of latest recommendations made by Kalpit Patel. Click to expand and see Kalpit Patel's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More